"FDA Clears Weight-Loss Drugs of Suicidal Thoughts Risk"

The FDA conducted a preliminary review and found no clear link between popular weight-loss drugs, such as Mounjaro, Ozempic, Wegovy, and Zepbound, and suicidal thoughts. While the agency cautioned that a small risk cannot be definitively ruled out, it emphasized that the benefits of these medications outweigh their risks when used according to FDA-approved labeling. The drugs, which mimic natural hormones and are part of the GLP-1 class, have been under scrutiny for potential side effects, including thoughts of suicide. A recent study also found no higher risk of suicidal thoughts among patients taking semaglutide for weight loss or diabetes.